NeuroScientific Biopharmaceuticals Limited Stock

Equities

NSB

AU0000012973

Biotechnology & Medical Research

Delayed Australian S.E. 00:18:01 2024-04-29 EDT 5-day change 1st Jan Change
0.052 AUD +8.33% Intraday chart for NeuroScientific Biopharmaceuticals Limited 0.00% +18.18%

Financials

Sales 2022 - Sales 2023 4.95M 3.26M 4.44M Capitalization 11.48M 7.56M 10.3M
Net income 2022 -10M -6.58M -8.97M Net income 2023 -1M -658K -897K EV / Sales 2022 -
Net cash position 2022 7.22M 4.75M 6.48M Net cash position 2023 4.91M 3.23M 4.41M EV / Sales 2023 1.33 x
P/E ratio 2022
-2.47 x
P/E ratio 2023
-10.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.16%
More Fundamentals * Assessed data
Dynamic Chart
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6% MT
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors CI
NeuroScientific Biopharmaceuticals CEO to Step Down MT
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023 CI
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023 CI
Neuroscientific Biopharmaceuticals Limited Announces Board Changes CI
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director CI
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7% MT
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods" CI
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12% MT
More news
1 day+8.33%
Current month+10.64%
1 month-5.45%
3 months+48.57%
6 months-13.33%
Current year+18.18%
More quotes
1 week
0.05
Extreme 0.048
0.05
1 month
0.05
Extreme 0.047
0.08
Current year
0.04
Extreme 0.035
0.08
1 year
0.04
Extreme 0.035
0.14
3 years
0.04
Extreme 0.035
0.54
5 years
0.04
Extreme 0.035
0.54
10 years
0.04
Extreme 0.035
0.54
More quotes
Managers TitleAgeSince
Chief Tech/Sci/R&D Officer - 22-03-31
Chief Operating Officer - 21-03-30
Director/Board Member - 17-09-28
Members of the board TitleAgeSince
Director/Board Member - 17-09-28
Chairman - 11-16
Director/Board Member - 12-04
More insiders
Date Price Change Volume
24-04-29 0.052 +8.33% 105 739
24-04-26 0.048 -7.69% 377,703
24-04-24 0.052 -1.89% 128,144
24-04-23 0.053 +1.92% 188,602
24-04-22 0.052 -1.89% 67,124

Delayed Quote Australian S.E., April 29, 2024 at 12:18 am

More quotes
NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.
More about the company